Yunji (YJ) Q2 2026 earnings review
Top-Line Collapse Obscures Cost-Cutting Gains; Capital Allocation Alarms Blaring
Yunji’s H1 2026 results paint a grim picture of a business shrinking rapidly. Revenue plummeted 39% YoY to RMB96.3M, driven by macro headwinds and the company's intentional cull of third-party merchants. While brutal cost-cutting narrowed the YoY net loss to RMB72.4M, sequentially, losses have re-accelerated compared to H2 2025. Most alarmingly, gross margins compressed despite the shift toward supposedly higher-margin private label health products. Capital allocation is a glaring concern: Yunji is pushing forward with a RMB600M headquarters build—dwarfing its RMB242M liquidity—and already took a RMB19.2M impairment charge on the half-constructed building.
🐂 Bull Case
Operating expenses were slashed by nearly 39% YoY. Fulfillment costs dropped by half. If the revenue base finally stabilizes, the leaner cost structure gives Yunji a much lower breakeven threshold.
Despite the massive drop in absolute sales, the 12-month repeat purchase rate held steady at a robust 69.15%, indicating that the remaining user base is highly loyal to the platform's private-label health offerings.
🐻 Bear Case
Sales have decelerated violently. The intentional strategy to pivot away from third-party marketplace merchants is destroying the top line faster than private-label sales can replace it.
A RMB600M headquarters project makes zero sense for a company with under RMB100M in half-year revenue and only RMB242M in liquid assets. The immediate impairment of this under-construction asset is a massive red flag.
⚖️ Verdict: 🔴🔴
Extremely Bearish. A 39% revenue drop combined with gross margin compression completely undermines the strategic pivot narrative. Add in bizarre, massive real estate expenditures that are already being impaired, and the risk profile is extremely high.
Key Themes
Real Estate CapEx & Bizarre Early Impairment
In a shocking capital allocation decision, Yunji is proceeding with a RMB600M headquarters construction project. The company ended H1 2026 with only RMB242.1M in total liquidity (cash, restricted cash, and short-term investments). Worse, management recorded a RMB19.2M impairment loss in H1 2026 on this exact property while the structural frame was merely 'topping out.' Impairing a brand-new, half-built asset highlights severe financial and strategic dysfunction.
Margin Narrative Contradicted by Data
Management claims that culling third-party merchants to focus on the 'Suyie' private label and 'organic healthy living' products will improve the business. However, the data contradicts this narrative: gross margin actually compressed from 47.3% in H1 2025 to 41.0% in H1 2026. If the new product mix was truly superior, margins should be expanding as the low-margin marketplace business is phased out.
Macroeconomic Weakness Exacerbates Internal Struggles
Management explicitly blamed 'soft consumer spending' and a challenging consumer environment in China for the top-line miss. This indicates that their niche, premium pivot (targeting organic/health segments) is running headfirst into a broader macroeconomic wall where consumers are trading down, not up.
Relentless Operating Expense Reductions
The sole bright spot preventing a total collapse of the income statement is aggressive cost control. Total operating expenses fell 38.8% YoY. Fulfillment expenses were cut in half to just RMB10.3M (10.7% of revenues), and G&A fell 49.1% (aided by a reduction in credit loss allowances). This decelerating cost curve is the only reason net losses narrowed YoY.
Sticky Core User Base
While absolute user numbers are clearly declining alongside revenue, the remaining cohort is highly engaged. The 12-month repeat purchase rate stood at a solid 69.15%. This suggests that the 'food-medicine homology' and organic health products do have a dedicated, albeit small, audience.
Other KPIs
Stable compared to the end of FY2025. However, against the backdrop of a RMB600M headquarters commitment and ongoing operating losses, this liquidity buffer is dangerously thin and implies severe future dilution or debt issuance.
Decelerating. Dropped from 47.3% in H1 2025. Management attributed this to derecognizing less incentive payables to inactive members compared to the prior year. This masks the underlying unit economics of the merchandise sales, which are failing to demonstrate the promised margin uplift from private labels.
Guidance
The company expects the total amount for the land acquisition and office building construction to reach RMB600M, funded through cash on hand and bank financing. This represents a massive cash drain for a micro-cap company currently generating under RMB100M in half-year revenue.
Key Questions
Headquarters Construction Rationale
With half-year revenues dropping below RMB100 million and total liquidity at RMB242 million, how does management justify continuing a RMB600 million headquarters build? Why not halt construction to preserve cash?
Immediate Asset Impairment
What specific 'impairment indicators' triggered a RMB19.2 million write-down on a building that is still actively under construction? Was this related to design flaws, cost overruns, or local real estate market conditions?
Gross Margin Contradiction
If the strategic pivot is successfully transitioning the company toward higher-margin private label organic products, why did gross margins compress by over 600 basis points year-over-year?
Revenue Floor
At what quarterly or half-year revenue run-rate do you expect the 'deliberate scale-back' of the marketplace business to finally bottom out, allowing for sequential top-line growth?